Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.70 |
| ▸ | FBP1 | P09467 | 2/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986222 | 0.90 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL11965408 | 0.85 | EGFR (0.78) | EGFRERBB2ABCG2 | |
| SCHEMBL2763594 | 0.85 | EGFR (0.82) | EGFRERBB2MEN1KMT2ATNK2 | |
| SCHEMBL6837615 | 0.84 | EGFR (1.00) | EGFRERBB2MEN1KMT2ATNK2 | |
| SCHEMBL2991673 | 0.84 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL2988440 | 0.84 | EGFR (1.00) | EGFRERBB2MEN1KMT2ATNK2 | |
| SCHEMBL29608178 | 0.84 | EGFR (1.00) | EGFRERBB2MKNK1FBP1ABCG2 | |
| SCHEMBL31060998 | 0.84 | EGFR (1.00) | EGFRERBB2FBP1ABCG2 | |
| SCHEMBL7221302 | 0.84 | EGFR (1.00) | EGFRERBB2MKNK1FBP1ABCG2 | |
| SCHEMBL1417740 | 0.84 | EGFR (1.00) | EGFRERBB2FBP1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | claimed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| CN-1370535-A | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | claimed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | claimed |
| US-10738086-B2 | Conjugates containing hydrophilic spacer linkers | ENDOCYTE INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3569251-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | Endocyte, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2176293-B1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10029022-B2 | Nuclear medicine diagnostic imaging agent | KYOTO UNIVERSITY (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170151340-A1 | Conjugates Containing Hydrophilic Spacer Linkers | ENDOCYTE INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170000912-A1 | Nuclear Medicine Diagnostic Imaging Agent | KYOTO UNIVERSITY (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170000912-A1 | Nuclear Medicine Diagnostic Imaging Agent | KYOTO UNIVERSITY (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | ELDER JAMES T (US) | 2002-11-14 | — | — | US | disclosed |
| CN-1370535-A | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | disclosed |
| EP-1230919-A2 | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | RARB, EBP, RXRA | EGFR 47/4885ERBB2 183/4885MEN1 4876/4885 |
| US-20170000912-A1 | Nuclear Medicine Diagnostic Imaging Agent | EGFR, FGFR1, ERBB2 | EGFR 1/4885ERBB2 3/4885MEN1 77/4885 |
| US-20170151340-A1 | Conjugates Containing Hydrophilic Spacer Linkers | CD44, HAVCR2, HCAR1 | EGFR 86/4885ERBB2 66/4885MEN1 2245/4885 |
| US-10029022-B2 | Nuclear medicine diagnostic imaging agent | EGFR, FGFR1, ERBB2 | EGFR 1/4885ERBB2 3/4885MEN1 77/4885 |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885MEN1 4018/4885 |
| US-10738086-B2 | Conjugates containing hydrophilic spacer linkers | CD44, HAVCR2, FCGR2A | EGFR 131/4885ERBB2 68/4885MEN1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.